Analysts Set Aardvark Therapeutics, Inc. (NASDAQ:AARD) PT at $30.63

Shares of Aardvark Therapeutics, Inc. (NASDAQ:AARD) have been given an average recommendation of “Moderate Buy” by the nine ratings firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation and eight have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $30.6250.

A number of research analysts recently commented on AARD shares. BTIG Research started coverage on shares of Aardvark Therapeutics in a research note on Friday, November 7th. They set a “buy” rating and a $26.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and set a $40.00 target price on shares of Aardvark Therapeutics in a research report on Tuesday, September 23rd. Jones Trading assumed coverage on Aardvark Therapeutics in a research note on Wednesday, October 1st. They issued a “buy” rating and a $33.00 price target on the stock. Bank of America cut their price objective on Aardvark Therapeutics from $26.00 to $25.00 and set a “buy” rating on the stock in a report on Thursday, August 28th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Aardvark Therapeutics in a report on Tuesday.

Insider Activity at Aardvark Therapeutics

In other Aardvark Therapeutics news, CFO Nelson Sun purchased 6,000 shares of the stock in a transaction dated Tuesday, September 9th. The shares were acquired at an average price of $8.07 per share, for a total transaction of $48,420.00. Following the completion of the acquisition, the chief financial officer owned 105,484 shares of the company’s stock, valued at $851,255.88. This represents a 6.03% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Tien-Li Lee purchased 10,000 shares of the company’s stock in a transaction that occurred on Monday, September 15th. The shares were acquired at an average cost of $9.66 per share, for a total transaction of $96,600.00. Following the completion of the transaction, the chief executive officer directly owned 1,543,384 shares of the company’s stock, valued at $14,909,089.44. This trade represents a 0.65% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have acquired 36,000 shares of company stock worth $305,630.

Hedge Funds Weigh In On Aardvark Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of AARD. Decheng Capital LLC purchased a new stake in shares of Aardvark Therapeutics in the first quarter worth approximately $29,419,000. Citadel Advisors LLC increased its stake in Aardvark Therapeutics by 5.9% in the 3rd quarter. Citadel Advisors LLC now owns 1,359,883 shares of the company’s stock valued at $18,073,000 after buying an additional 76,151 shares during the period. Laurion Capital Management LP lifted its position in Aardvark Therapeutics by 6.1% in the 3rd quarter. Laurion Capital Management LP now owns 1,049,721 shares of the company’s stock worth $13,951,000 after buying an additional 60,653 shares in the last quarter. Cormorant Asset Management LP acquired a new stake in Aardvark Therapeutics during the first quarter valued at $6,009,000. Finally, Vanguard Group Inc. raised its stake in shares of Aardvark Therapeutics by 20.6% during the 3rd quarter. Vanguard Group Inc. now owns 555,721 shares of the company’s stock worth $7,386,000 after purchasing an additional 94,744 shares in the last quarter.

Aardvark Therapeutics Stock Up 3.2%

Aardvark Therapeutics stock opened at $9.98 on Thursday. The firm has a 50-day moving average price of $12.05 and a two-hundred day moving average price of $11.52. The firm has a market capitalization of $217.26 million and a price-to-earnings ratio of -4.71. Aardvark Therapeutics has a 52-week low of $4.88 and a 52-week high of $19.58.

Aardvark Therapeutics (NASDAQ:AARD) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.75) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.07.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.